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The botanical, Astragalus membranaceus, is a therapeutic in traditional Chinese medicine. Limited literature exists on the overall
in vivo effects of A. membranaceus on the human body. This study evaluates the physiological responses to A. membranaceus by
measuring leukocyte, platelet, and cytokine responses aswell as body temperature and blood pressure in healthy individuals after the
in vivo administration ofA. membranaceus. A dose-dependent increase inmonocytes, neutrophils, and lymphocytes was measured
8–12 hours after administration and an increase in the number of circulating platelets was seen as early as 4 hours. A dynamic change
in the levels of circulating cytokines was observed, especially in interferon-𝛾 and tumor necrosis factor-𝛼, IL-13, IL-6, and soluble
IL-2R. Subjective symptoms reported by participants were similar to those typically experienced in viral type immune responses
and included fatigue, malaise, and headache. Systolic and diastolic blood pressure were reducedwithin 4 hours after administration,
while body temperature mildly increased within 8 hours after administration. In general, all responses returned to baseline values
by 24 hours. Collectively, these results support the role of A. membranaceus in priming for a potential immune response as well as
its effect on blood flow and wound healing.
1. Introduction
Botanical medicines are plant-derived products which have
increasingly come under significant investigation for their
potential therapeutic applications [1–3]. The use of botanical
medicines worldwide is increasing significantly [4, 5]. A 2007
National Institute of Heath Survey revealed that 44% of
Americans 50–59 years of age and 38% of adults less than
50 years of age have used some form of Complementary and
Alternative Medicine (CAM), including botanical medicines
[6]. Approximately $14.8 billion dollars in out-of-pocket
expenditures for nonvitamin, nonmineral, natural products
were spent that year (compared to $47.6 billion spent on
pharmaceutical drugs) [7]. Due to the growing demand
for alternative therapies and the general public notion that
botanical medicines are safe, some physicians prefer or are
considering referral to CAM specialists for their expertise
[8–10]. However, evidence based characterization is typically
limited regardingmany of these therapies, justifying the need
for further research.
Originally described in Shen Nong’s Classic of Materia
Medica over two thousand years ago, the botanicalAstragalus
membranaceus (AM) has been used extensively in traditional
Chinese medicine to support and enhance the immune
system, to treat various conditions, including viral infection,
fatigue, decreased appetite, debility, nonhealingwounds, liver
and kidney disease, and cancers [11, 12]. Traditionally, AM is
made into a decoction inwhich pieces of rootwere boiled into
soups and then removed prior to consumption.
The presumptive active constituents of AM include
polysaccharides, saponins, flavonoids, and astragalosides [13,
14]. Recent evidence has also suggested an active compo-
nent role of lipopolysaccharides provided by endosymbiotic
bacteria present on the root of AM [15, 16]. Astragalus
polysaccharides (APS) have demonstrated immunopotenti-
ating properties such as increasedmurine B-cell proliferation
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and cytokine production [17]. Numerous in vitro studies and
limited in vivo studies and clinical trials have demonstrated
intriguing indications for the use of AM, particularly as
an immunomodulator to prevent and treat heart disease,
nephritis, bacterial infection, and viral illnesses (especially
respiratory infections and chronic hepatitis) and as an
adjunct therapy for cancer, HIV, and atopic disease [15, 18–
24]. Several animal studies have shown the ability of AM
to restore and enhance immunologic function in the cases
of either immunosuppression or infection including HSV,
HIV, HBV, and viral myocarditis [16, 22–27]. The antiviral
and wound healing properties of AM are proposed to be
indirect viamodulation of proinflammatory cytokines induc-
ing leukocyte and platelet mobilization. Current research
in animal models suggests that AM may have a significant
clinical effect on cell proliferation and wound healing [28–
30]. Although significant research has been conducted on
AM, in vivo studies are limited. The research presented
provides an evaluation of the physiological response to AM
following in vivo administration of this botanical.
2. Materials and Methods
2.1. Botanical Extract Preparation. Dried Astragalus mem-
branaceus root slices were purchased from Mayway Corpo-
ration (Oakland, CA). Dried AM was validated using herbal
pharmacopoeia monographs. Six hundred grams of dried
AM was ground in a 1 gallon stainless steel Hamilton Beach
blender, transferred to a clean amber colored gallon glass jar,
and 2220 milliliters of boiling distilled water was added to
the ground root. After six hours, 780mL of 190 proof ethanol
was added for a final ratio of 1 : 5 (weight of botanical to
volume of liquid).Themixture was kept at room temperature
for 3 weeks, followed by separation of the liquid portion
from the solid herb portion using a mechanical press. The
extracted liquid was filtered using unbleached paper filters,
pooled, and dispensed in amber colored bottles. To eliminate
any physiological responses due to ethanol, the original 25%
ethanol based AM extract was vacuum-dried for 3 hours.
Final ethanol concentrations were measured to be 2–4%.
A vehicle control sample was prepared from 25% ethanol
that was similarly dried for 3 hours. For standardization
purposes, a sample of the extract was dried and found to
have a concentration of nonvolatile solutes of 92.6mg/mL
extract. Since definitively active constituents present in AM
are unknown, we cannot calculate the concentration of active
constituent(s) present in the extract. Therefore, this value
serves as a reference measure for relative activity.
2.2. Participants. This case series study included 2 healthy
males (29 yo and 47 yo) and 2 healthy females (24 yo and
27 yo). Criteria for healthy individuals included the absence
of known chronic disease, the absence of illness including
HIV and HCV, and no use of any medications at the time
of the study. Participants were informed that they must be
without symptoms of illness at the time of the study and
that they must adhere to a controlled diet for 4 days prior to
beginning the study (including no alcohol or use of known
immunomodulatory foods). The study was approved and
overseen by the Arizona State University and Southwest
College of Naturopathic Medicine (SCNM) Institutional
Review Boards (Protocol 208-11). Each participant received
and completed a written informed consent form prior to
participation in the study. Most data was acquired from the
47 yo male and 24 yo and 27 yo females; however a 29 yo
male replaced the 27 yo female during toxicity testing due to
relocation.
2.3. In Vivo Administration. The ethanol-reduced AM
extract or vehicle was administered to three healthy subjects
at indicated doses and relative to bodyweight. Doses included
0.25mL/kg, 0.75mL/kg, and 1.5mL/kg. The AM extract
was administered sublingually over a period of 20 minutes
followed by ingestion. Trials occurred on separate days with
at least 4 weeks in between trials.
Rationale for dosages used is as follows: for acute condi-
tions, doses of AM often range from 1 to 25 g/day. For this
study, we wanted to investigate acute changes over a 24-hour
period related to the immune response. Therefore, based on
average 70 kg adult, the highest dose of 1.5mL AM extract/kg
body weight was calculated with an average adult receiving
an extract from 20 g dried AM. Similarly, the 0.75mL/kg and
0.25mL/kg doses were based on an average adult receiving
extract from 10 g to 3.3 g dried AM, respectively.
2.4. Venipuncture. Blood was collected into heparinized
tubes (BD vacutainer cell preparation tube with sodium
heparin) 0, 4, 8, 12, and 24 hours after administration of the
AM extract. Samples were sent to an external lab (Lab Corps)
for routine processing including flow cytometry and cytokine
assay. Arizona State University and the Southwest College of
NaturopathicMedicine (SCNM) Institutional Review Boards
approved the collection and processing of all blood samples.
2.5. Blood Analysis. Blood sent to external labs was processed
through standard cell counting and flow cytometry, and a
full blood profile was done which included the following:
white blood cell populations, including total white blood
cells, lymphocytes,monocytes, neutrophils, and platelets, and
lymphocyte subpopulations including total T-cells (CD3+),
T-helper cells (CD3+CD4+), T-cytotoxic cells (CD3+CD8+),
B-cells (CD19+), and NK-cells (CD56+). A cytokine assay
was also performed by the third-party lab via ELISA and
included the following cytokines: IL-1𝛽, IL-2, sIL-2R, IFN-
𝛾, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-12, and TNF-𝛼.
Liver (AST, ALT, bilirubin, and ALP) and kidney (potassium,
sodium, BUN, creatinine, and BUN/creatinine ratio) panels
were tested to assess potential toxicity at 1, 12, and 24 h after
ingestion of AM or vehicle.
2.6. Physiological Responses. The subjective physiological
reactions experienced by each participant were reported
at each blood draw. Symptoms were reported and then
rated subjectively on an intensity scale of 1–10 (10 highest
intensities). Blood pressure and body temperature (taken
orally) were recorded by laboratory technicians at each blood
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draw. Physiologic responses were completed with both the
AM trials and the vehicle control trial.
2.7. Statistical Analysis. Statistical analyses were performed
using SPSS Statistical Analysis Software. Differences
between time points (0 versus 12 hours and 0 versus 24
hours) were analyzed using paired 2-tailed “𝑡” tests and were
considered statistically significant if 𝑝 < 0.05.
2.8. Ethics Statement. All research involving human partic-
ipants was approved by the Southwest College of Naturo-
pathic Medicine Institutional Review Board (Protocol: 208-
11). Informed consent was obtained from all participants and
all clinical investigations were conducted according to the
principles expressed in the Declaration of Helsinki.
3. Results
The majority of leukocytes in the body are located in
organs of the lymphatic system or connective tissues proper.
Circulating white blood cells represent a fraction of the
total white blood cell population in the body, and changes
from baseline values are useful in interpreting activity of
the immune system. For example, inflammation can result
from infection or various disease states and cause known
characteristic changes in circulating leukocytes. To define any
specific changes induced by the in vivo administration of AM,
an analysis of leukocyte populations including total white
blood cells, peripheral bloodmononuclear cells (lymphocytes
and monocytes), and polymorphonuclear cells (neutrophils)
was completed. The observed effects were measured over a
24-hour time period, after in vivo administration of AM.
This analysis was conducted on 3 separate occasions, each for
varying doses of AM including 0.25mL/kg, 0.75mL/kg, and
1.5mL/kg. A control test was done with 1.5mL/kg vehicle.
As Figure 1 indicates, treatment with the vehicle control
had almost no effect on absolute numbers of leukocytes
while treatment with AM demonstrated statistically signifi-
cant increases in cell numbers above initial/baseline values;
𝑝 values were typically significant at 8 and 12 hours. Along
with increases in cell numbers, atypical lymphocytes were
notably present 8 and 12 hours after treatment (classified
by increased granularization, increased size, and chromatin
decondensation) and indicate lymphocyte activation. The
observed increases in cell number also appeared to be dose-
dependent and this was consistent across all subjects (com-
pare 0.25mL/kg dose with 0.75mL/kg dose). Fold changes
were calculated to best represent the magnitude of change
that occurred over the 24-hour period and Figure 1 shows
the maximal fold change for each individual subject. Total
WBCs increased on average (based on 𝑛 = 3) 1.3x above
baseline values at the lowest dose and 1.53x at the highest
dose (𝑝 values 0.042 and 0.011, resp.). Similarly, in comparing
0.25mL/kg, 0.75mL/kg, and 1.5mL/kg doses, neutrophils
increased from an average (based on 𝑛 = 3) of 1.4x, 1.68x, and
1.73x above baseline values; lymphocytes increased by 1.46x,
1.63x, and 1.73x, and monocytes increased by 1.53x, 1.53x,
and 1.76x above baseline values, respectively. Furthermore,
as doses increased, the data also typically became more
significant. For example increases in numbers of neutrophils
were associated with 𝑝 values, at each of the three doses of
AM, of 0.049, 0.034, and 0.007, respectively.
The timing of these changes is noteworthy and consistent.
In all subjects, maximal peak values were obtained between
8 and 12 hours. In all cases, baseline values returned by 24
hours after administration of AM. Although increases in cell
population were observed following AM administration, cell
numbers never exceeded ranges regarded as normal for the
human population (normal range indicated in the figure).
It is clear that while changes to leukocyte populations were
significant compared to baseline values, neither leucopenia
nor leukocytosis were observed.
We next sought to characterize changes in numbers
of lymphocyte population subsets circulating in the blood.
For this experiment, subjects were administered the highest
dose of AM (1.5mL/kg) on two separate occasions and
lymphocyte populations were measured 0 and 12 hours
after administration. As shown in Figure 2, increases in T-
and B-cells including total CD3+, CD3+CD4+, CD3+CD8+,
and CD19+ lymphocytes were observed. CD19+ (B-cells)
increased on average 1.66x and 1.60x above baseline values
for trials 1 and 2, respectively (𝑝 < 0.001). Similarly, the
average increases for trials one and two demonstrated that
total CD3+ cells increased by 1.46x and 1.66x (𝑝 = 0.002),
CD3+CD4+ (T-helper cells) increased by 1.53x and 1.73x
(𝑝 < 0.001), and CD3+CD8+ (T-cytotoxic cells) increased
by 1.33x and 1.5x (𝑝 = 0.035). Collectively, fold changes
ranged from 1.2x to 2.0x above baseline values in these cell
populations. While increases are statistically significant from
baseline values (𝑝 values including both trials range from
𝑝 < 0.001 to 0.035 between the subsets), all cell population
values remained within normal physiological limits. This
trend of increases in circulating B- and T-cell subsets suggests
that AM may be mobilizing these cells. Conversely, natural
killer (NK) cells (CD56+) were shown to mildly decrease
or remain unchanged. Subjects responded very similarly
between the two separate experiments shown in Figure 2
adding confidence to the physiological effect of AM. For
example, compare the initial (𝑡 = 0 hrs) and final (𝑡 = 12 hrs)
levels of CD3+ cells for subject 2 between trials 1 and 2.
Since AM is clinically reported for use in damaged
tissues such as diabetic wound healing, we next evaluated
changes to platelet counts in relation to increasing doses
of AM in vivo [31, 32]. Wound healing is a complex and
dynamic process involving a highly regulated sequence of
biochemical and cellular events. Platelets contribute to this
process by providing the initial hemostasis that occurs after
tissue injury and by producing growth factors responsible
for the regeneration of damaged tissues. As seen in Figure 3,
platelet counts were moderately increased by statistically
significant values in the 0.75mL/kg dose and 1.5mL/kg dose.
In addition, a dose-dependent trend reflected in absolute
increases from baseline values and significance was observed.
Average fold increases in circulating platelets for the three
increasing doses were 1.07x (𝑝 = 0.058 at 8 h), 1.17x (𝑝 =
0.048 at 8 h), and 1.20x (𝑝 = 0.035 at 4 h; 𝑝 = 0.031 at 8 h)
above baseline values, respectively. While the two highest
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Figure 1: AM effect onwhite blood cell populations. Subjects 1, 2, or 3 (indicated by blue, red, and green lines, resp.) were administered vehicle
or varying concentrations of AM extract (0.25, 0.75, and 1.5mL extract/kg body weight). Blood draws were performed 0, 4, 8, 12, and 24 hours
after administration to measure total cell population numbers. Cells measured include total white blood cells, neutrophils, lymphocytes, and
monocytes. Peak fold changes relative to baseline (𝑡 = 0 hours) are indicated. Normal physiological ranges of the different cell populations
are indicated by black bars.
doses resulted in significant increases, changes occurred
within normal physiological ranges and there was no evi-
dence of thrombocytopenia or thrombosis at any point in
time. The analysis also demonstrated that peak values are
obtained between 4 and 8 hours after administration of
AM. Comparatively, peak values for leukocyte counts were
observed between 8 and 12 hours. A return to baseline values
was observed across all subjects by 12 to 24 hours after
administration of AM.
Since in vivo administration of AM has been reported
to differentially modulate cytokine activity, we contin-
ued our analysis by reviewing intercellular communication
between immune populations through changes to circulating
cytokines [33]. As Figure 4 illustrates, this analysis was
done after the administration of the highest dose of AM at
1.5mL/kg and assay of serum for various cytokines including
interleukins (IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, and IL-
13), soluble IL-2 receptor (IL-2R), interferon gamma (IFN-𝛾),
and tumor necrosis factor alpha (TNF-𝛼) at 0 and 12 hours.
Circulating levels of these cytokines were quantified with
a minimum limit of detection at 5 pg/mL. Increases above
the limit of detection were seen in IL-2R, IFN-𝛾, IL-6, IL-
13, and TNF-𝛼 across all three subjects. Induction of IL-1𝛽
was observed in two subjects, while induction of IL-2, IL-10,
and IL-12 was observed in only one subject each. IL-4 and
IL-5 were not induced above the limit of detection in any
participant.Themost significant changes were seen in IL-2R,
IFN-𝛾, and TNF-𝛼 (𝑝 = 0.056, 𝑝 = 0.018, and 𝑝 = 0.046,
resp.). These results are consistent with the promotion of a
Th1 immune response by AM due to the increase of IFN-𝛾
and TNF-𝛼 and the absence of IL-4.
The potential for AM to cause liver or kidney toxicity
following ingestion was assessed to determine safety at the
highest dose (1.5mL/kg). For all liver enzyme and kidney
function tests performed, no statistically significant differ-
ences weremeasured at 12 and 24 h after administration (data
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Figure 2: AM effect on lymphocyte subset populations. Subjects (1, 2, or 3) were administered AM at a 1.5mL extract/kg body weight dose.
Blood drawswere performed 0 (blue bars) and 12 (red bars) hours after administration and lymphocyte subset cell populationsweremeasured.
The experiment was repeated twice. Peak fold changes relative to baseline (𝑡 = 0 hours) are indicated. Normal physiological ranges of the
different cell populations are indicated by black bars.
not shown). Similarly, the vehicle had no effect on liver and
kidney tests (data not shown).
In addition to these studies, we evaluated symptomatic
outcomes following administration of AM. Physiological
symptomatic responses were dose-dependent with the most
dramatic results observed at the highest AM dose (data
not shown). As shown in Figure 5(a), typical “flu-like”
symptoms were reported by all participants. The symptoms
included fatigue, malaise, headache, and a reduced capacity
to mentally focus. Symptoms were first reported between 2
and 4 hours and reached maximal values between 6 and 10
hours after ingestion of AM. All participants demonstrated
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Figure 3: AM effect on circulating platelets. Subjects 1, 2, or 3 (indicated by blue, red, and green lines, resp.) were administered vehicle
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a decline in symptoms by 12 hours and by 24 hours no
symptoms were reported by any individual. The average
peak intensity ratings for these three symptoms were 3.67/10
(malaise), 4.67/10 (headache), and 5/10 (fatigue); although
peak intensities occurred at different time points. Statistical
significance, as represented by 𝑝 values, for headache and
fatigue ranged from 0.015 to 0.057. While ratings for malaise
showed trending in two out of three subjects, one subject
experienced only very minor fatigue and for a much shorter
duration than the others. Thus the 𝑝 value was >0.05. These
symptoms are consistent with those typically reported in
proinflammatory sickness [34, 35]. No other significant
physiological symptoms were reported by the subjects.
Our study also monitored changes to body temperature
over the 24-hour time period after administration of the
1.5mL/kg dose of AM. Compared to the vehicle control, two
of the three subjects showed significant trending in increased
body temperatures (Figure 5(b)). The other subject did not
demonstrate a change in body temperature. The maximum
value noted was 99.3∘F and may be interpreted as a mild
fever response. Maximum temperatures were observed by 8
hours after administration of AM and temperatures returned
to baseline values by 24 hours.
To further understand the effects of AMon blood flow, we
also measured blood pressure at each blood draw during the
1.5mL/kg trial. As shown in Figure 6, a decrease in systolic
pressure (ranging from −1.11x to −1.17x baseline values) by an
average of −1.13x below baseline values was seen consistently
across participants 4 hours after administration. In contrast,
the vehicle control led to an average increase of +0.37x
above baseline values for systolic blood pressure. Similarly,
participants also showed consistent decreases in diastolic
blood pressure ranging from −1.10x to −1.17x with an average
of −1.14x in response to AM 4 hours after ingestion. Again
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performed 0 (blue or light grey bars) and 12 (red or black bars) hours after administration and specific cytokine levels measured. Detection
limits for all cytokines were 5 pg/mL (5 pg/mL limit is indicated by the black line). Blue and red bars indicate values at or above 5 pg/mL.
Light grey and black bars indicate values less than 5 pg/mL (nondetectable). Cytokine levels above normal physiological ranges are indicated
by ∗. 𝑝 values for IL-2R, IFN-𝛾, and TNF-𝛼 are shown.
these results differ from those seen with the vehicle control
with increased diastolic pressure of 1.16x baseline values on
average. Systolic and diastolic changes were significant with
𝑝 values of 0.007 and 0.003 at 4 hours, respectively. With
regard to the timing of response, participants followed very
similar trends where maximal changes were observed at the
4-hour timepoint.This result was similar to the time response
observed with changes to circulating platelets. A return to
baseline values was seen in all participants 8–24 hours after
ingestion of AM. Despite significant decreases in systolic and
diastolic values, the lowest values seen did not drop below
normal physiological limits of systolic pressure of 90mmHg
or diastolic pressure of 60mmHg and hypotension was not
induced at any point in time.
4. Discussion
Our data supports a correlation between the purported
physiological effects of the immunomodulatory botanical,
AM, and changes in cytokine gene expression and immune
cell circulation. In vivo, AM induced significant elevations
in both total and specific leukocyte populations but changes
remained within normal physiological limits. Specifically,
CD3+,CD3+CD4+ andCD3+CD8+, andCD19+ lymphocyte
populations were induced while natural killer (CD56+) cell
populations were unchanged. In addition, total neutrophil
and monocyte numbers increased suggesting a global mobi-
lization of leukocytes into the blood stream following AM.
Previous data from microarray analysis after the in vitro
treatment of peripheral blood mononuclear cells (PBMCs)
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Figure 5: Physiological responses in subjects following administration of AM. Subjects 1, 2, or 3 (indicated by blue, red, and green lines, resp.)
were administered vehicle or 1.5mL extract/kg bodyweight dose of AMextract. (a) Symptoms of fatigue,malaise, and headachewere recorded
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Body temperature was measured orally 0, 4, 8, 12, and 24 hours after administration of the extract.
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Figure 6: AM effects on blood pressure. Subjects 1, 2, or 3 (indicated by blue, red, and green lines, resp.) were administered vehicle or 1.5mL
extract/kg body weight dose of AM extract. Blood pressure (systolic and diastolic) was measured 0, 4, 8, 12, and 24 hours after administration
of the extract.
with AM suggested that proinflammatory and Th1 specific
cytokines were primarily upregulated [15]. In this regard, AM
has been reported to modulate cytokine expression fromTh2
toward Th1 in cancer and chronic viral infection [36, 37].
Our present in vivo data demonstrate a potential for priming
toward a Th1 response where AM lead to the significant
induction of Th1 cytokines, IFN-𝛾 and TNF-𝛼, along with a
moderate induction of proinflammatory IL-6. The presence
of IL-6 mediates fever and induces the acute phase response
in the liver as well as acting as a differentiation factor to B-
cells,monocytes, andmacrophages and can act to regulate the
development of a Th1 immune response through the induc-
tion of SOCS-1 and IL-4 [38]. However, our data do not show
induction of IL-4 in serum following AM administration
even though IL-6 is induced. IFN-𝛾 leads to increased Th1
responses during infection or immunization and inhibitsTh2
cell proliferation. IFN-𝛾 is involved inmacrophage activation,
the generation of cell-mediated immunity, and upregulation
of antiviral and antimicrobial effector molecules, and, in
conjunctionwith TNF-𝛼, can induceNF-𝜅B responsive genes
synergistically [39]. TNF-𝛼 itself is a pyrogen and an acute
phase protein that promotes the inflammatory response,
especially during diapedesis, and is highly expressed in
Th1-activated T-cells. Alternately, with induction of the Th2
cytokine, IL-13was observed. IL-13 plays a nonredundant role
with IL-4 in generating resistance to gastrointestinal parasites
and intracellular organisms, increases mucus production,
and generates IgE responses [40]. Despite being traditionally
considered a Th2 cytokine, recent characterization of IL-13
has shown that it can be produced by IFN-𝛾+ Th1 cells and
by Th17 cells [41]. Finally, soluble IL-2R was significantly
induced in all subjects. It is normally expressed on antigen
activated T lymphocytes and leads to T-cell proliferation. Its
secretion indicates the presence of activated T-cells and can
be an indicator of infection, neoplasms, and autoimmunity
[42]. The levels of soluble IL-2R were increased 1.5–2.5-fold
following AM treatment; however levels are lower than those
seen in patients with chronic hepatitis infection (1.6–4-fold),
acute EBV infections (7-fold), or B-cell cancer patients (up to
6.4-fold) but are similar to levels seen in autoimmune patients
with rheumatoid arthritis (2-fold) [43–46].
Both direct and immune modulatory activities may
explain the reported antibacterial effects of AM. It is recog-
nized that when IFN-𝛾 and TNF-𝛼 bind to their respective
macrophage receptors, they stimulate the release of nitric
oxide which results in increased destruction of bacteria [47].
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In addition to cytokines, polysaccharides isolated from AM
are also potent inducers of nitric oxide [48]. Alternately,
polysaccharides isolated from AM have recently been shown
to suppress Treg function by downregulating the production
of IL-10 in a murine model of bacterial sepsis [49]. This may
explain, at least in part, some of the clinical success for AM
reported in the literature regarding antibacterial activity.
Our analysis of immune stimulation by AM related to
white blood cell populations was of interest. As the dose
of AM increased, absolute numbers of total leukocytes,
neutrophils, lymphocytes, and monocytes also increased.
Concurrently, increasing doses resulted in higher statistical
significance as seen by an associated decrease in 𝑝 values.
Therefore, immune stimulation by AM is likely producing a
dose-dependent response to changes in white blood cell pop-
ulations. It is noteworthy that these changes remain within
normal physiological ranges since therapeutic applications
would not necessarily desire pathological immune responses
such as leukocytosis or leukopenia. Historically, AM has
been used to support and enhance the immune system,
for instance in conditions of debility and viral infection.
Given the rapid peak in circulating WBC populations we
suspect that AM stimulates a mobilization of the immune
cells into circulation from peripheral tissues/organs rather
than hematopoietic formation of new cells from the bone
marrow. It is possible that AM acts to stimulate immune cell
mobilization leading to broad, systemic scanning of potential
antigens as if “positioning” the immune cells for activity. It is
then reasonable to infer that following mobilization, with no
antigen present to continue activation of the immune cascade,
the response is subsequently diminished and circulating cell
populations are normalized by 24 hours after treatment. Sur-
prisingly, administration of AM did not increase circulating
levels of NK-cells. NK-cells are an important component in
the antiviral immune response and are typically activated
in response to IL-2, IL-12, IL-15, IL-18, and CCL5. Of these
cytokines, we only assayed IL-2 and IL-12, each of which was
induced in separate subjects. These results may suggest some
level of specificity to the innate response induced by AM.
Regarding blood flow and wound healing, previous lit-
erature and anecdotal evidence suggests that AM may be
associated with an increased risk of bleeding tendencies,
improved endothelial cell function, improved blood glucose
control, improved cardiovascular function overall, and blood
pressure lowering effects [50–52]. Our results demonstrated
a minor increase in platelets within 4–8 hours after admin-
istration of AM; a faster response than that observed in
the leukocyte population. Like the leukocyte populations,
there was an increase in absolute numbers of circulating
platelets with higher dosing of AM. Our previous in vitro
AM microarray studies identified putative genes induced by
AM which are associated with angiogenesis, wound healing,
and blood pressure modulation. It is known that the role of
platelets is to provide the initial hemostasis that occurs after
tissue injury and to produce growth factors responsible for
the regeneration of damaged tissues such as platelet derived
growth factor (PDGF), transforming growth factor (TGF),
and endothelial growth factor (EGF). Our cytokine analysis
showed significant increases in IL-6, which is involved
in PDGF-induced cell proliferation [53]. Similarly IL-13 is
known to induce the release of TGF from epithelial cells [54].
While our studies support the notion that AM may induce
wound healing through changes in specific cytokine popula-
tions and numbers of circulating platelets, further studies are
needed to determine a more complete understanding of the
relationships between cytokine induction, cellular responses,
and clinical results.
Our results demonstrated a decrease in blood pressure
following administration of AM. Clinically, both whole
botanical applications and isolated constituents of AM, such
as astragaloside IV, have been shown to be beneficial in
ischemic heart disease, heart failure, myocardial infarction,
and relief of anginal pain [55]. This may be due in part to a
vasodilatory effect leading to the observed reduction in both
systolic and diastolic pressure. Indeed, IL-6, IL-13, andTNF-𝛼
are also known inducers of vasodilation [56–58].
An increase in body temperature has been historically
recognized since ancient times as an indication of infection
or inflammation. Current research demonstrates that T-
cytotoxic cells are affected by mild hyperthermia through
changes to cell membranes, which then mediate cell function
and differentiation [59].There is little to no significant data in
the literature on the effect of AM on body temperature. Since
individuals deviate only slightly from the standard value of
98.6∘F, our results suggest a mild effect on body temperature
due to AM. Two out of three of our subjects demonstrated
minor although significant increases in temperature to a
maximum value of 99.3∘F in one subject. Furthermore, there
is a clear trend in those subjects which mirrors that of the
WBC response withmaximumvalues between 8 and 12 hours
and a subsequent return to baseline by 24 hours. Increases
in activated white blood cells leads to the production of
endogenous pyrogens such as IL-1, IL-6, and TNF-𝛼. Our
results likely indicate an increase in temperature as part of
the coordinated steps of normal immune activation.
To understand this response even further, subjective
symptoms including fatigue, malaise, and headache were
observed to occur soon after ingestion of AM and returned
to baseline values by 24 hours. Subjects also reported a lack
of mental focus.The early presence of these symptoms (often
before 4 hours) indicates a likely prodrome type of response
which parallels the notion that immune cell populations are
being induced for wide spread systemic scanning. TNF-𝛼 is
an acute phase response proinflammatory cytokine involved
in pain activation including headache, malaise, and fatigue
[60, 61]. Proinflammatory cytokines, IL-6 (all 3 patients) and
IL-1𝛽 (2 patients), were also measurable and, together with
TNF-𝛼, likely resulted in symptoms associated with immune
activation.
Our study provides analyses of the physiological
responses following administration of AM to a limited
number of subjects. To the best of our knowledge, no other
study has elucidated such an overall response under this
specific group of parameters and in healthy individuals. Since
there has been an increase in the use of botanical therapies,
including herbal medicine, health food, and cosmetics, this
research is relevant to CAM practitioners, primary care
physicians, and other medical doctors alike. The significant
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potential for therapeutic and clinical application as well as
the growing interest for scientific evidence and expertise in
the use of botanical medicine creates a clear need for in vivo
analysis and further characterization of AM.
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